<div id="readability-page-1"><p><span>Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report)</span> was upgraded by investment analysts at Guggenheim to a &#34;strong-buy&#34; rating in a report released on Monday,Zacks.com reports.</p><div><p><span></span><span>Get <strong>Aclaris Therapeutics</strong> alerts:</span></p></div><ul><li>3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices </li></ul><p>ACRS has been the topic of several other reports. Wall Street Zen downgraded Aclaris Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Sunday, April 12th. Piper Sandler increased their price target on Aclaris Therapeutics from $7.00 to $11.00 and gave the stock an &#34;overweight&#34; rating in a report on Tuesday. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Aclaris Therapeutics in a research report on Friday, March 27th. UBS Group  set a $10.00 price target on shares of Aclaris Therapeutics in a report on Thursday, April 16th. Finally, Craig Hallum began coverage on Aclaris Therapeutics in a research note on Friday, January 30th. They issued a &#34;buy&#34; rating and a $10.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one  has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of &#34;Buy&#34; and an average price target of $11.00.</p><p><b>Check Out Our Latest Stock Analysis on ACRS</b></p><h2>Aclaris Therapeutics Stock Performance</h2><p>Shares of NASDAQ:ACRS opened at $4.75 on Monday. Aclaris Therapeutics has a one year low of $1.16 and a one year high of $4.89. The stock has a market capitalization of $663.39 million, a price-to-earnings ratio of -8.96 and a beta of 0.76. The company has a 50-day simple moving average of $3.77 and a 200-day simple moving average of $3.22. </p><p>Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.01). The company had revenue of $1.30 million for the quarter, compared to analysts' expectations of $2.07 million. Aclaris Therapeutics had a negative return on equity of 52.04% and a negative net margin of 829.58%. As a group, research analysts forecast that  Aclaris Therapeutics will post -0.63 EPS for the current fiscal year. </p><h2>Insiders Place Their Bets</h2><p>In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard sold 300,000 shares of the business's stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $4.53, for a total transaction of $1,359,000.00. Following the completion of the sale, the insider owned 13,950,000 shares of the company's stock, valued at approximately $63,193,500. The trade was a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Insiders own  5.60% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase &amp; Co. boosted its position in  Aclaris Therapeutics by 21.6% during the 3rd quarter. JPMorgan Chase &amp; Co. now owns 758,576 shares of the biotechnology company's stock worth $1,441,000 after purchasing an additional 134,784 shares during the period.  AXQ Capital LP purchased a new position in  Aclaris Therapeutics in the third quarter valued at about $27,000.  Bank of New York Mellon Corp grew its position in shares of  Aclaris Therapeutics by 1.7% during the first quarter. Bank of New York Mellon Corp now owns 207,024 shares of the biotechnology company's stock worth $776,000 after buying an additional 3,507 shares in the last quarter.  SG Americas Securities LLC grew its holdings in  Aclaris Therapeutics by 73.6% during the 1st quarter. SG Americas Securities LLC now owns 26,767 shares of the biotechnology company's stock worth $100,000 after acquiring an additional 11,344 shares in the last quarter.  Finally, Strs Ohio acquired a new position in  Aclaris Therapeutics in the first quarter worth about $60,000. 98.34% of the stock is owned by institutional investors and hedge funds. </p><h2>About Aclaris Therapeutics</h2> (Get Free Report)<p>Aclaris Therapeutics, Inc <span>NASDAQ: ACRS<span></span></span> is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company's pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.  </p><p>Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Aclaris Therapeutics</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNSUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNSUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Aclaris Therapeutics Right Now?</h2><p>Before you consider Aclaris Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aclaris Therapeutics wasn't on the list.</p><p>While Aclaris Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ACRS

<p>Guggenheim has upgraded Aclaris Therapeutics (NASDAQ: ACRS) to a "strong-buy" rating. The stock has seen mixed ratings from analysts, with two giving a strong buy, five a buy, and one a sell. Aclaris has a market cap of $663.39 million and a current price of $4.75, with a one-year high of $4.89. The company reported a quarterly loss of $0.16 EPS, missing estimates. Recent insider trading saw major shareholder Braden Michael Leonard sell 300,000 shares. Institutional investors hold 98.34% of the stock, indicating strong institutional interest.</p>

Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Guggenheim